Devdatt (Dev) Kurdikar serves as the President and Chief Executive Officer of embecta. Previously, Dev was the President and CEO of Cardiac Science Corporation (CSC), a global leader in the manufacturing and marketing of automated external defibrillators (AEDs) for public access, education, police, and fire and rescue markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Dev’s leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical.
Prior to that role, Dev was the Vice President and General Manager, Men’s Health, an important growth business within Urology and Pelvic Health at Boston Scientific Corp (NYSE: BSX). Dev was in the same role at American Medical Systems (AMS) and led the Men’s Health business through a significant business turnaround, and then the carve-out and sale to BSX, where Dev led the business through its integration into BSX. Before joining AMS, Dev served as Vice President, Marketing, Baxter International Inc. (NYSE: BAX), where he worked directly with the company’s top executives on a global commercial initiative to drive market access. Previously, he was the Vice President, Marketing for the Infusion Systems business for the U.S. region where he played a key role in stabilizing the business while under a consent decree, and launched a new wireless enabled infusion pump. In his 11 years with Baxter, Dev held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company.
Dev holds a Bachelor in Chemical Engineering from the University of Bombay (India). He earned a Master of Science in Chemical Engineering from Washington State University (Washington), a Ph.D. in Chemical Engineering from Purdue University (Indiana), and a Master of Business Administration from Washington University (Missouri).
Ginny Blocki serves as the SVP, Global Marketing & Product Management of embecta. Previously, Ginny was with Baxter as the Head of US Medication Delivery Marketing (Infusion Systems, IV Fluids, Disposables and Pharmacy WorkFlow Manager). Prior to her role at Baxter, Ginny was the Vice President Specialty Products with Assertio Therapeutics where she played a key role in product development of a priority asset and multiple business development endeavors while leading marketing and sales efforts.
Before joining Assertio, Ginny served as Head of Global Marketing Molecular Diagnostics at Abbott Laboratories, overseeing and leading all commercial activities. Prior to Abbott, Ginny served as the Vice President, Head of Global Marketing Immunology with Baxter and Baxalta (spin off from Baxter) where she played a vital role in the Global Immunology business. Throughout her career, Ginny has held leadership roles of increasing responsibility in general management, marketing, strategy, market access, and sales. She has a proven track record of developing successful brands and businesses through different phases of product development, working with cross-functional teams on a regional, national, and global scale.
Ginny holds a Bachelor of Science degree in finance from Indiana University. She’s also a Kellogg School of Management alum having completed the Executive Scholar Program in General Management.
Tom Blount serves as the SVP, President, North America of embecta. Previously, Tom spent 6 years with BD, as VP/GM US region Diabetes Care, WW VP/GM Infusion and Global Marketing leader for Diabetes Care and additional upstream marketing roles. Prior to BD, Tom spent the last 16 years at Sanofi in various roles including Associate VP of Diabetes Value and Access, Associate VP of Toujeo Value & Access, Associate VP Lixisenatide Family Marketing, Sr. Director of Marketing Strategy for Sanofi Genzyme R&D, Sr. Director of Marketing Strategy for the Fibrosis Wound Repair Global Strategy Unit, Director of General Therapeutics Mature Brands, Director & Commercial Alliance Leader for XYZAL Marketing, and many other roles in Sales and Marketing.
Tom has vast launch experience in a variety of sales, marketing and market access roles and in a variety of disease areas including diabetes. Tom also spent 5 years on active duty finishing as a Captain in the United States Army. He holds a Bachelor of Science degree in German/French from the United States Military Academy at West Point and a Master of Science in International Relations from Troy University – European Campus.
Jean Casner serves as SVP, Chief Human Resources Officer, and has over 30 years of global human resources strategy, design and operations experience across a range of industries. Most recently, she served as Senior Vice President and Chief Human Resources Officer for Renalytix, PLC, an emerging in-vitro diagnostic medical device company, where she was responsible for building the HR function in preparation for rapid growth following FDA approval of its groundbreaking diagnostic test, KidneyIntelX.dkd. Prior to Renalytix, Jean served as SVP and Chief Human Resources Officer of Cantel Medical Corp., a global medical products company focused on infection prevention products. There, she was responsible for the global human capital strategy, encompassing talent development, talent acquisition, succession planning, total rewards, benefits, diversity, equity and inclusion and HR operations. Previously, Jean also held HR leadership positions of increasing responsibility in the areas of HR Operations and Compensation and Benefits at the National Basketball Association (NBA), Merck & Co., The Dial Corporation (now Henkel), Johnson & Johnson, and ORC (now Mercer).
Jean holds a Bachelor of Arts degree in English from the University of Virginia.
Shaun Curtis serves as SVP, Global Manufacturing & Supply Chain. Shaun is responsible for leading global operations, consisting of 1,200 associates with plants located in Ireland, USA, and China. Accountability includes the performance of Safety, Quality, Delivery, Financials, Continuous Improvement and launching new products across the manufacturing network.
Previously, Shaun was the Manufacturing Director at BD Plymouth, UK (part of the Integrated Diagnostic Solutions Business), responsible for a plant manufacturing billions of Vacutainer tubes and blood collection needles a year. Shaun also represented Operations as part of the North-West European Leadership team where he worked with senior leaders developing growth strategies for the region.
Prior to joining BD, Shaun was the Engineering Manager at Cooper Standard Automotive, Plymouth, UK. The manufacturing Plant was a Tier 1 supplier of extruded weather seals to the car industry and supplied to companies including Ford, Rover, Honda, and GM. The role involved leading an engineering team responsible for all engineering activities in a plant of more than 600 associates. Before this, Shaun worked at Pall Filtration, UK.
Shaun holds a Master of Business Administration from Northampton University, UK. He earned an Honors Degree in Mechanical Engineering from Plymouth University. He also achieved a Higher National Diploma in Mechanical Engineering at Swindon College.
Jake Elguicze serves as as embecta’s Chief Financial Officer. Previously Jake was with Teleflex, a $2.5 billion global provider of medical technologies, where he served as the company's Treasurer and Head of Investor Relations. Jake is a CPA and began his career in public accounting with PricewaterhouseCoopers before spending 8 years at Motorola in operating finance roles.
Jake joined Teleflex in 2006 to build out the financial planning and analysis function. He assumed responsibility for investor relations in 2009 and added the Treasurer role in 2011, where he transformed the capital structure to support the company’s new M&A strategy.
Jake earned a Bachelor of Science in Accounting from the University of Scranton in Scranton, PA, and a Master of Business Administration in Finance from St. Joseph’s University in Philadelphia, PA.
Jeff Mann serves as the General Counsel and Head of Business Development for embecta. Jeff brings 22 years of medical device and law firm experience to embecta, including leadership in M&A, securities, corporate governance, intellectual property, commercial transactions, compliance and litigation, and he has deep roots in the medical, pharmaceutical and biotechnology sectors.
Most recently, he served as General Counsel and Corporate Secretary of Cantel Medical Corp., a global medical products company focused on infection prevention products, where he was responsible for the global legal, compliance, and environmental health and safety teams. He also led several business development projects, including the eventual sale of Cantel to Steris plc for $4.6 billion. Simultaneously, he held a year-long assignment as global leader of Cantel’s R&D team, managing a team of 130 associates based in Germany, Italy, the United Kingdom and the U.S.
Prior to Cantel, he spent 14 years with Boston Scientific Corporation in roles of increasing responsibility, including M&A, venture capital investments, SEC and corporate governance patent strategy, litigation, and business unit support for the $3 billion MedSurg group. He also served on the Board of Directors of Preventice Solutions and as Chair of its Compensation Committee.
Jeff holds a Bachelor of Science in Civil and Environmental Engineering from Lafayette College in Easton, PA, and a J.D. from Boston College Law School, magna cum laude.
Slobodan Radumilo serves as the SVP, President International for embecta. Slobodan is also Chair to the Diabetes Sector Group at Med-tech Europe. Prior to this role, Slobodan worked at Medtronic between 1997 and 2016, holding roles of increasing responsibility, most recently as Vice-President of Neuromodulation for Europe and Canada, Regional Vice President for Central and Eastern Europe and Central Asia, and Regional Vice President for Central and Eastern Europe, Greece and Israel. In his regional roles, Slobodan managed all of Medtronic operations in more than 25 countries of the world with population of half a billion. Slobodan had been a member of the Officer Group of Medtronic Inc. since 2011.
Slobodan’s experience has been characterized by his ability to work with governments around the world to improve awareness, access, and affordability of healthcare. Throughout his career, Slobodan has always sought to bring innovation to the center of his business activities and has a passion for developing outstanding talent and forming winning teams.
Slobodan holds a Bachelor of Science degree in Electrical Engineering, a Master of Science degree in Biomedical Engineering and a Diploma in Management from the University of Zagreb (Croatia), as well as a Diploma in Leadership from the Glasgow Caledonian University.
Colleen Riley serves as the SVP, Chief Technology Officer for embecta. Previously, Colleen was the Senior Vice President of Innovation and Development for Terumo Blood and Cell Technologies. Under Colleen’s leadership she advanced both existing and new product platforms beyond traditional scope of medical devices and therapy manufacturing to include services, software, and data management. These advancements drove continued growth throughout the particularly challenging COVID-19 pandemic.
Prior to that role, she served as Vice President Science and Technology and Vice President Regulatory Affairs and Compliance at Stryker Orthopedics. During this tenure, she led a regulatory transformation that delivered the pivotal Mako robotic clearances and expanded 3D printing capabilities. These initiatives led to optimized orthopedic implant design, improved functional outcomes and patient satisfaction, and drove market-leading growth. She also served as Vice President, Global Research for Novartis, AG, and Chief Operation Officer for Nexis Vision Inc. In both these roles, she led the organization into new white space, high growth opportunities, significantly increasing the value of their respective portfolios.
Colleen held several roles of increased responsibility at Johnson & Johnson Vision, including Vice President, Professional Development and Medical Affairs. Additionally, she was lead designer and developer of new product pipelines across multiple therapeutic categories. This included category altering products for both developed and emerging markets. Her efforts helped generate more than $2 billion in worldwide sales and market-leading growth.
A Doctor of Optometry, Colleen started her professional career in private practice, before joining the Indiana University School of Optometry as Clinical Faculty, Residency Program Supervisor and Co-Director of the Clinic. Colleen earned a Bachelor of Arts in Chemistry, a Master of Science in Physiological Optics and an OD, Doctor of Optometry, degree from Indiana University.